A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE IIIB, INTERNATIONAL STUDY EVALUATING THE SAFETY OF OBINUTUZUMAB ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED OR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Intervention/treatment:
OBINUTUZUMAB / BENDAMUSTINE / FLUDARABINE PHOSPHATE / CYCLOPHOSPHAMIDE / CHLORAMBUCIL
Medical condition:
LYMPHOCYTIC LEUKEMIA
Protocol code:
MO28543
Control number:
167068
Status:
Closed
Approved:
September 05, 2013
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT01905943
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Medical Communications
Organization
Hoffmann-La Roche
Phone:
800 821-8590
Sponsor
HOFFMANN-LA ROCHE LIMITED

Locations

Manitoba

Cancer Care Manitoba
Winnipeg, Manitoba, R3E 0V9

New Brunswick

Regional health authority A vitalite health network
Moncton, New Brunswick, E1C 8X3

Nova Scotia

Queen Elizabeth II Health Sciences Centre; Oncology
Halifax, Nova Scotia, B3H 2Y9

Ontario

Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials
Barrie, Ontario, L4M 6M2

Quebec

Centre de sante et de services sociaux Rimouski Neigette
Rimouski, Quebec, G5L 5T1
Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie
Greenfield Park, Quebec, J4V 2H1
Hopital Maisonneuve- Rosemont; Oncology
Montreal, Quebec, H1T 2M4

Saskatchewan

CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie
Québec, Saskatchewan, G1J 1Z4
Saskatoon Cancer Centre; Uni of Saskatoon Campus
Saskatoon, Saskatchewan, S7N 4H4

Results

See the results from the trial NCT01905943. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?